(+)-Biotin-PEG8-NHS Ester manufacturers
- Biotin-PEG8-NHS ester
-
- $0.00 / 500mg
-
2024-04-02
- CAS:2143968-03-8
- Min. Order: 500mg
- Purity: >98.00%
- Supply Ability: 500mg
|
| | (+)-Biotin-PEG8-NHS Ester Basic information |
| Product Name: | (+)-Biotin-PEG8-NHS Ester | | Synonyms: | (+)-Biotin-PEG8-NHS Ester;Biotin-PEG8-SPA;4,7,10,13,16,19,22,25-Octaoxa-28-azatritriacontanoic acid, 33-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-29-oxo-, 2,5-dioxo-1-pyrrolidinyl ester | | CAS: | 2143968-03-8 | | MF: | C33H56N4O14S | | MW: | 764.88 | | EINECS: | | | Product Categories: | SiChem;peg;Biotin | | Mol File: | 2143968-03-8.mol |  |
| | (+)-Biotin-PEG8-NHS Ester Chemical Properties |
| density | 1.29±0.1 g/cm3(Predicted) | | pka | 13.90±0.40(Predicted) |
| | (+)-Biotin-PEG8-NHS Ester Usage And Synthesis |
| Biological Activity | Biotin-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | (+)-Biotin-PEG8-NHS Ester Preparation Products And Raw materials |
|